 Predictive Oncology Inc saw its consolidated revenue for the first quarter ended March 31, 2022, rise to 314,568, up from the 280,317 it recorded in the corresponding quarter of 2021, which it believes points to solid potential for growth in the upcoming period. The increase was driven by a 6 gain in the Skyline segment STREAMWAY System product sales and initial revenue from the zPREDICTA segment, the company said, adding that the zPREDICTA segment has an encouraging sales pipeline, including additional revenue from current transactions that are expected to be recognized in the next several quarters. 